Cardiovascular Diseases, Primary Prevention, Risk Reduction
Conditions
Brief summary
The China PEACE SMARTER trial is a cluster ramdomized trial aiming to assess the effectiveness of village doctor-led tailored health management on risk reduction of high-risk individuals for cardiovascular disease.
Detailed description
In this study, investigators aim to develop a series of intervention strategies for cardiovascular disease (CVD) prevention through village doctor-led tailored health management in individuals with elevated risk, then assess their effectiveness through a cluster randomized trial. Investigators hypothesize that the village doctor-led tailored health management can reduce the CVD risk and improve risk factor control of the high-risk subjects through 12 months of follow-up. Around 4200 subjects from 120 villages in mainland China who are considered to be eligible according to inclusion and exclusion criteria will be enrolled to the study. The eligibility criteria is: Individuals aged 35 or above who are in high risk for CVD (10-year ASCVD risk ≥10%), able to use smart phone, and contracted with the local family doctor. Patients with history of CVD or severe illnesses, pregnancy, cognition or communication problems are excluded from the study. The selected villages will be assigned (1:1) to either control group (usual care) or intervention group (village doctor-led tailored health management). The primary outcome is the change in 10-year ASCVD risk from baseline to 12 months. Follow up visits will be conducted every 3 months.
Interventions
COMBINATION_PRODUCTVillage doctor-led tailored health management
Investigators will sketch features of cardiovascular risk factor combinations for the high-risk subjects and accordingly set tailored promotion targets for them. Subjects will receive individualized consultation about their cardiovascular risk profile and tailored health management led by village doctors. They will receive tailored health text messages pushed by village doctors 3 times a week, including contents in physical activity, healthy diet, smoking abstinence, responsible alcohol drinking, sleep, and medication adherence. They will be provided with a smart band, and supposed to daily wear the smart band to collect health data. The progress of tailored promotion targets will be evaluated every 3 months, and feedback will be given in the form of virtual rewards and punishments: completed (a virtual golden egg) and failed (a virtual bomb). According to the number of virtual golden eggs, participants could redeem project gift in real life.
Sponsors
China National Center for Cardiovascular Diseases
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
35 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Aged 35 or above; * High CVD risk which defined as 10-year ASCVD risk ≥10% based on China-PAR prediction model; * Ownership of a smart phone and being able to use apps; * Being contracted with the local family doctor (village doctor); * Willing to participate and able to sign informed consent.
Exclusion criteria
* CVD history, including myocardial infarction (MI), stroke, heart failure, severe arrhythmia, or peripheral artery disease, or having received percutaneous coronary intervention (PCI) or coronary artery by-pass grafting operation (CABG); * Severe illnesses, such as cancer, or severe hepatic and renal dysfunction; * Women during pregnancy, lactation, or plan to have children in the next year; * Having problems in cognition or communication, or limited daily activities.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 10-year ASCVD risk score | 12 months | Changes in 10-year ASCVD risk score from baseline to 12 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Lifetime ASCVD risk score | 12 months | Changes in lifetime ASCVD risk score from baseline to 12 months |
| Blood pressure | 12 months | Changes in systolic and diastolic blood pressure from baseline to 12 months |
| Fasting plasma glucose (FPG) | 12 months | Changes in fasting plasma glucose (FPG) from baseline to 12 months |
| Non-HDL cholesterol | 12 months | Changes in Non-HDL cholesterol from baseline to 12 months |
| Smoke abstinence | 12 months | Changes in proportion of daily smoking persons from baseline to 12 months |
| Physical activity | 12 months | Changes in proportion of subjects with insufficient physical activity (\<3000 MET min/wk) from baseline to 12 months |
| Weight change | 12 months | Changes in proportion of subjects who are overweight and obesity from baseline to 12 months |
Other
| Measure | Time frame | Description |
|---|---|---|
| Exploratory Outcome: Medication adherence | 12 months | Changes in proportion of subjects who report taking the full dose of prescribed medications ≥6 days per week among all necessary subjects from baseline to 12 months |
| Exploratory Outcome: MACEs | 12 months | Major adverse cardiovascular events, including occurrence of death, myocardial infarction, stroke, and cardiovascular hospitalization |
Countries
China
Outcome results
None listed